Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786512 · ClinicalTrials.gov registry record · Phase 2
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 544
- Enrollment target
NCT01786512: Completed Phase 2 study, sponsored by Cytokinetics.
NCT01786512 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 544 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (309% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786512, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 544 participants
- Enrollment target
Study Summary
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Omecamtiv Mecarbil Matrix F1 Formulation
- DRUG Omecamtiv Mecarbil Matrix F2 Formulation
- DRUG Omecamtiv Mecarbil Swellable Core Technology F2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2013-02-26 |
| Est. Completion | 2015-08-19 |
| Phase | Phase 2 |
What the finished NCT01786512 record still lists
NCT01786512 is an interventional study that assigns participants to a tested intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (309% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01786512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01786512 about?
NCT01786512 is a clinical study titled "COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure". The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks...
What is the current status of trial NCT01786512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 544 participants. The study started on 2013-02-26. Estimated completion is 2015-08-19.
What interventions are being tested in trial NCT01786512?
The interventions under investigation include: Placebo (DRUG), Omecamtiv Mecarbil Matrix F1 Formulation (DRUG), Omecamtiv Mecarbil Matrix F2 Formulation (DRUG), Omecamtiv Mecarbil Swellable Core Technology F2 (DRUG).
Who is sponsoring clinical trial NCT01786512?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01786512's enrollment target sits among peer trials
544 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI